PEGS Boston 2017 | Generation of BiKEs and TriKEs

Dr. Jeffrey Miller outlines what he considers to be some of the greatest obstacles to developing BiKEs and the new class of molecules called TriKEs, describes his method and what is unique about his approach, details unexpected discoveries, shares advice for introducing novel antibody therapeutics in the clinical setting and talks about what he considers some of the most exciting new developments emerging for bispecific antibody killer engagers. For more information, please visit http://www.PEGSummit.com/Bispecific-Antibodies-For-Oncology/